U.S. Markets for Respiratory Care Products, June 2016
U.S. Markets for Respiratory Care Products, June 2016
$4,750.00
The annual U.S. economic burden of respiratory disease is more than $106 billion. Appropriate therapy can reduce direct healthcare costs as well as indirect costs such as lost worker productivity. The combined U.S. market for respiratory products totalled more than $4.4 billion in 2015.
Publisher: MedTech Insight
- Description
- Contents
- Samples
The annual U.S. economic burden of respiratory disease is more than $106 billion. Appropriate therapy can reduce direct healthcare costs as well as indirect costs such as lost worker productivity. The combined U.S. market for respiratory products totaled more than $4.4 billion in 2015, and is expected to climb at a rate of 7% over the forecast period. The sleep apnea management products market (including PAP products and accessories) is expected to experience the most dollar sales ($2.2 billion in 2015), as well as the greatest growth over the forecast period (8%). In the blood gas monitoring systems market, the increasing popularity of POC analyzers has led to the rapid emergence of technological innovation, resulting in the introduction of lighter, more compact, less costly systems. POC systems currently account for nearly 40% of the overall U.S. blood gas analyzers market.
This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the U.S ventilator systems, blood gas monitoring systems, pulmonary function assessment products, sleep apnea management products, and airway management accessories market.
Table of Contents
EXECUTIVE SUMMARY …………………………………………………………………………. ES-1
i. Ventilator systems ……………………………………………………………….. ES-1
ii. Blood gas monitoring systems ……………………………………………….. ES-3
iii. Pulmonary function assessment products ……………………………….. ES-9
iv. Sleep apnea management products ……………………………………… ES-10
v. Airway management accessories …………………………………………. ES-14
vi. Combined market discussion ………………………………………………. ES-18
vii. Methodology ……………………………………………………………………… ES-23
Exhibit ES-1: Ventilators, market forecast, 2015–20 …………………………………….. ES-4
Exhibit ES-2: Blood gas monitoring systems, market forecast, 2015–20 …………. ES-7
Exhibit ES-3: Pulmonary function assessment products, market forecast, 2015–20 …………………………………………………………………………… ES-11
Exhibit ES-4: Sleep apnea management products, market forecast, 2015–20 .. ES-15
Exhibit ES-5: Airway management accessories, market forecast, 2015–20 …… ES-19
Exhibit ES-6: Respiratory care products, combined market forecast, 2015–20 . ES-21
1. RESPIRATORY DISEASE OVERVIEW ……………………………………………… 1-1
1.1 Acute respiratory distress syndrome …………………………………………. 1-1
1.1.1 Etiology…………………………………………………………………… 1-2
1.1.2 Epidemiology …………………………………………………………… 1-3
1.2 Asthma …………………………………………………………………………………. 1-5
1.2.1 Etiology…………………………………………………………………… 1-5
1.2.2 Epidemiology …………………………………………………………… 1-5
1.3 Chronic obstructive pulmonary disease ……………………………………… 1-6
1.3.1 Chronic bronchitis …………………………………………………….. 1-6
1.3.1.1 Etiology ……………………………………………………. 1-6
1.3.2 Emphysema ……………………………………………………………. 1-8
1.3.2.1 Etiology ……………………………………………………. 1-9
1.3.3 Epidemiology …………………………………………………………… 1-9
1.4 Cystic fibrosis ………………………………………………………………………. 1-11
1.4.1 Etiology…………………………………………………………………. 1-11
1.4.2 Epidemiology …………………………………………………………. 1-11
1.5 Pneumonia ………………………………………………………………………….. 1-12
1.5.1 Etiology…………………………………………………………………. 1-12
1.5.2 Epidemiology …………………………………………………………. 1-14
U.S. Markets for Respiratory Care Products Executive Summary
2016 Medtech Insight | Pharma Intelligence ES-2 #A482
1.6 Respiratory failure ………………………………………………………………… 1-14
1.6.1 Etiology…………………………………………………………………. 1-14
1.6.2 Epidemiology …………………………………………………………. 1-14
1.7 Restrictive lung disease …………………………………………………………. 1-16
1.7.1 Etiology…………………………………………………………………. 1-16
1.7.2 Epidemiology …………………………………………………………. 1-18
1.8 Sleep apnea ………………………………………………………………………… 1-20
1.8.1 Etiology…………………………………………………………………. 1-20
1.8.2 Epidemiology …………………………………………………………. 1-20
1.9 Tuberculosis ………………………………………………………………………… 1-21
1.9.1 Etiology…………………………………………………………………. 1-21
1.9.2 Epidemiology …………………………………………………………. 1-23
Exhibit 1-1: Acute respiratory distress syndrome, selected facts and figures ……. 1-4
Exhibit 1-2: Asthma, selected facts and figures ……………………………………………. 1-7
Exhibit 1-3: Chronic obstructive pulmonary disease, selected facts and figures 1-10
Exhibit 1-4: Cystic fibrosis, selected facts and figures …………………………………. 1-13
Exhibit 1-5: Pneumonia, selected facts and figures …………………………………….. 1-15
Exhibit 1-6: Respiratory failure, selected facts and figures …………………………… 1-17
Exhibit 1-7: Restrictive lung disease, selected facts and figures …………………… 1-19
Exhibit 1-8: Obstructive sleep apnea, selected facts and figures ………………….. 1-22
Exhibit 1-9: Tuberculosis, selected facts and figures …………………………………… 1-24
Exhibit ES-1: Ventilators, market forecast, 2015–20
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
U.S. Markets for Respiratory Care Products 
Sign up to the